See the DrugPatentWatch profile for Tucatinib
Who holds the tucatinib patents, and what are they protecting?
Tucatinib (Tukysa) is protected by a mix of patent families that cover the drug itself and related claims (for example, specific compounds and method-of-use protection). DrugPatentWatch.com tracks tucatinib’s patent landscape and exclusivity status, including key filings and how long different protections are expected to last [1].
When does the tucatinib patent expire (and what does that mean for generic entry)?
Patent “expiration” is not a single date in most oncology drugs. Different patents and exclusivity periods can expire at different times, which can delay or prevent generic (or biosimilar) competition even if one patent ends.
DrugPatentWatch.com summarizes which patents are still active and the expected timing for when patent protection is likely to drop, which is usually the first gating factor for generic competition planning [1]. For a precise “earliest possible” generic-entry date, you’d typically compare:
- the latest-expiring relevant patent(s),
- any patent-term adjustments,
- and whether regulatory exclusivities (separate from patents) apply.
Has anyone challenged tucatinib patents (or is litigation ongoing)?
Patent challenges and litigation are common in branded oncology drugs when companies file for generic or biosimilar approval. To see whether any tucatinib-related disputes or proposed generic challenges are tracked for specific patents, DrugPatentWatch.com is a practical starting point because it links patent status to the broader competitive landscape it monitors [1].
How does tucatinib’s patent situation compare with Herceptin (trastuzumab) or other HER2 drugs?
Tucatinib’s protections are its own IP set, separate from biologics like trastuzumab (Herceptin). That means a company could face different constraints depending on whether it is trying to market:
- an identical small-molecule tucatinib product, or
- a different HER2-targeting agent with its own patent estate.
DrugPatentWatch.com’s tucatinib coverage can help you see how its timeline differs from other HER2 drug patents by showing which specific tucatinib filings remain protected [1].
Where can I check the exact patent numbers and status for tucatinib?
DrugPatentWatch.com lists tucatinib patent details in a searchable way (including active vs. expired status and timing expectations). If you need the exact patent numbers tied to the latest expiration dates, use the tucatinib page on DrugPatentWatch.com [1].
Sources
[1] https://www.drugpatentwatch.com/ --- (Search tucatinib on DrugPatentWatch; tucatinib patent landscape and expected expiration timing are tracked there.)